01 A BRIEFING FOR MOCANNTRADE MEMBERS
Three things, shifting at once.
| Functional and medical products are maturing into a category of their own. The federal posture, for the first time in decades, is open to change. And the clinical conversation is catching up to what patients have been telling clinicians for years. None of these is the story on its own. Together, they're starting to describe a different industry — one where the patient, the regulator, and the operator can finally talk about the same thing.
|
 |
|
01 THE PRODUCT MIX
Functional is the through-line. Sleep. Pain. Recovery. Anxiety. Focus. Patients are increasingly shopping for an outcome, not an experience. Brands and retailers oriented around specific use cases — and the education that supports them — see a different customer profile than the legacy adult- use shopper: larger baskets, higher repeat rates, less price-sensitivity at shelf. |
02 THE FEDERAL POSTURE
The federal door is open. On April 23, 2026, the DOJ and DEA placed FDA-approved marijuana products and products under a qualifying state medical license into Schedule III — effective immediately. An expedited administrative hearing on the broader rescheduling of all marijuana from Schedule I to III begins June 29, 2026. For the first time, state- regulated medical product has a federal classification that recognizes it, and a defined pathway forward. |
03 THE CLINICAL CONVERSATION
Science is catching up to the patient. The endocannabinoid system has been mapped for thirty-plus years; peer- reviewed cannabinoid research continues to compound. Physicians are engaging the category in more structured ways — through programs like MoCannTrade's HET committee and the regulated hemp-derived CBD pathway the FDA has begun to define. "Is it medicine?" is becoming "what dose, for what indication, for which patient?" |
|
WHAT TO WATCH How quickly use-case-led merchandising and education shift basket size, repeat rate, and category mix relative to the legacy adult-use shopper. |
WHAT TO WATCH The June 29 administrative hearing record, FDA-approved and state-licensed product categories moving first under the new Schedule III classification, and how state medical programs evolve in response. |
WHAT TO WATCH Physician engagement programs —including MoCannTrade's HET committee —and where peer-reviewed clinical evidence accelerates the dose-for-indication conversation. |
| THE CONVERGENCE |
Each force, on its own, is incremental. Together, they describe a different industry — one with a clearer through-line from research bench to product shelf.
|
 |
 |
Surfside is an omnichannel advertising and analytics platform. We help dispensaries and brands understand demand, reach verified shoppers, and measure performance against the outcomes that move a business forward. We are not legal or financial advisors; our job is to help operators see the market clearly and act on what they see. CONTINUE THE CONVERSATION - www.surfside.io |
This briefing is informational and reflects publicly available information at the time of writing, including the DOJ press release of April 23, 2026 and the DEA's notice of administrative hearing scheduled to begin June 29, 2026. Surfside is not a legal, financial, regulatory, or medical advisor. Statements about federal regulation, rescheduling, and hemp- derived CBD pathways are descriptive of current public-domain reporting, not predictions or guidance. Operators should consult qualified counsel for decisions specific to their business. © 2026 Surfside.